Key Points
- COO Ian Hodgson sold 2,415 shares on Feb. 3 at an average price of $8.09 for $19,537.35, cutting his stake by 4.44% to 51,927 shares (about $420,089), per an SEC filing.
- Recent stock and financials: CRBP opened at $7.95 with a 1‑year range of $4.64–$20.56, market cap ≈$139.5M, 50/200‑day moving averages of $8.89/$10.72, and it reported a quarterly EPS of ($1.90) that missed estimates; analysts expect -4.23 EPS for the year.
- Analyst consensus is cautiously positive: MarketBeat shows a "Moderate Buy" consensus (1 Strong Buy, 8 Buy, 2 Sell) with an average price target of $44.38.
Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP - Get Free Report) COO Ian Hodgson sold 2,415 shares of the company's stock in a transaction dated Tuesday, February 3rd. The stock was sold at an average price of $8.09, for a total transaction of $19,537.35. Following the completion of the transaction, the chief operating officer owned 51,927 shares in the company, valued at approximately $420,089.43. The trade was a 4.44% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website.
Corbus Pharmaceuticals Price Performance
CRBP opened at $7.95 on Thursday. Corbus Pharmaceuticals Holdings, Inc. has a 1 year low of $4.64 and a 1 year high of $20.56. The business's 50-day moving average is $8.89 and its two-hundred day moving average is $10.72. The firm has a market capitalization of $139.52 million, a PE ratio of -1.44 and a beta of 2.86.
Corbus Pharmaceuticals (NASDAQ:CRBP - Get Free Report) last posted its quarterly earnings data on Wednesday, November 12th. The biopharmaceutical company reported ($1.90) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.80) by ($0.10). As a group, sell-side analysts expect that Corbus Pharmaceuticals Holdings, Inc. will post -4.23 EPS for the current year.
Analyst Upgrades and Downgrades
A number of research analysts have issued reports on CRBP shares. Piper Sandler reissued an "overweight" rating and issued a $51.00 price target on shares of Corbus Pharmaceuticals in a report on Monday, October 20th. Wedbush raised their target price on Corbus Pharmaceuticals from $31.00 to $38.00 and gave the company an "outperform" rating in a research report on Monday, October 20th. Benchmark reissued a "reduce" rating on shares of Corbus Pharmaceuticals in a report on Monday, October 20th. HC Wainwright reiterated a "buy" rating and set a $40.00 price target on shares of Corbus Pharmaceuticals in a research report on Monday, October 20th. Finally, Royal Bank Of Canada lowered their target price on shares of Corbus Pharmaceuticals from $55.00 to $53.00 and set an "outperform" rating on the stock in a research note on Thursday, November 13th. One equities research analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating and two have assigned a Sell rating to the stock. According to data from MarketBeat.com, Corbus Pharmaceuticals has an average rating of "Moderate Buy" and a consensus price target of $44.38.
Check Out Our Latest Research Report on Corbus Pharmaceuticals
Hedge Funds Weigh In On Corbus Pharmaceuticals
Several institutional investors have recently bought and sold shares of the company. ADAR1 Capital Management LLC purchased a new position in shares of Corbus Pharmaceuticals in the third quarter valued at approximately $129,000. Corton Capital Inc. acquired a new position in shares of Corbus Pharmaceuticals in the second quarter worth $86,000. Marshall Wace LLP acquired a new stake in shares of Corbus Pharmaceuticals in the second quarter valued at $137,000. Baker Avenue Asset Management LP purchased a new position in Corbus Pharmaceuticals in the second quarter valued at $138,000. Finally, Y Intercept Hong Kong Ltd purchased a new stake in Corbus Pharmaceuticals during the 2nd quarter worth about $141,000. 64.64% of the stock is owned by institutional investors and hedge funds.
About Corbus Pharmaceuticals
(
Get Free Report)
Corbus Pharmaceuticals Holdings, Inc is a clinical-stage biopharmaceutical company dedicated to the development and commercialization of therapeutic candidates for rare, life-threatening inflammatory and fibrotic diseases. The company's lead investigational therapy, lenabasum, is a synthetic, oral cannabinoid receptor type 2 (CB2) agonist designed to resolve chronic inflammation by harnessing the body's innate resolution pathways. Corbus operates by advancing small-molecule compounds through preclinical and clinical studies to address unmet medical needs in autoimmune and inflammatory disorders.
Lenabasum is currently under evaluation in a Phase 3 clinical trial for diffuse cutaneous systemic sclerosis (dcSSc) and in a Phase 2 study for cystic fibrosis–related inflammation.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
